What Shield costs you, by how you are covered
| Your coverage | What you pay for Shield | What happens after a positive result |
|---|---|---|
| Original Medicare (Part B), 45 to 85, average risk, no symptoms | $0 if the provider accepts assignment, once every 3 years | Follow-up colonoscopy covered as a screening test: $0, unless a polyp is removed (then 15% coinsurance for the provider and, at a hospital outpatient department or surgery center, 15% to the facility; no deductible) |
| Medicare Advantage | Federal rules bar cost sharing for in-network Medicare-covered screening (42 CFR 422.100(k)); Guardant warns MA patients may still owe, so ask whether Guardant's lab is in your network | Same rule for the screening colonoscopy in network; ask the plan before testing |
| Private insurance | Not required at $0: the federal preventive rule follows the USPSTF, which does not include blood tests. Guardant names UnitedHealthcare as covering Shield | Ask the plan in writing whether the colonoscopy counts as screening |
| VA Community Care or TRICARE | Guardant lists both as covering Shield | Ask the program |
| Paying cash | $1,495, the rate Guardant lists "in the event the test is not fully covered by insurance" | You pay for the colonoscopy separately |
That last row is unusual. For routine lab tests, cash prices run well above Medicare's rate: in our lab price comparison, the cheapest cholesterol panel bought alone, fees included, costs 1.72 times what Medicare pays for the test and the blood draw. Shield's cash price and Medicare's payment are the same $1,495: CMS approved Shield as an advanced diagnostic laboratory test on March 10, 2025, and its list shows the $1,495 rate.
Who qualifies under Medicare's rule
Medicare's national coverage determination for colorectal screening (NCD 210.3) covers non-invasive biomarker tests like Shield "once every 3 years" for people 45 to 85 who have no signs or symptoms of colorectal disease and are at average risk, meaning no personal history of adenomatous polyps, colorectal cancer or inflammatory bowel disease, and no family history of colorectal cancer, adenomatous polyps or the inherited syndromes. The ordering clinician must give you "information about the test performance and the importance of a follow-on colonoscopy if the test returns a positive result."
The rule changed in 2026. The version effective June 8, 2026 (claims systems updated by January 4, 2027) renamed the category from blood-based to non-invasive biomarker tests and set two ways a test can qualify: at least 90% sensitivity with 87% specificity, or at least 79% sensitivity with 90% specificity, both from the FDA labeling, plus a requirement to meet the FDA's post-approval study to keep coverage. Medicare covers Shield under this rule. In the ECLIPSE study it had 83.1% sensitivity for cancer and 89.6% specificity for advanced neoplasia, which Guardant's materials round to 90%. Since January 1, 2025, a federal regulation (42 CFR 410.37(k)) has counted the colonoscopy after a positive blood or stool test as part of a complete screening, outside the usual frequency limits, which is why Medicare charges nothing for it unless a polyp is removed.
What Shield finds and what it misses
The FDA approved Shield on July 26, 2024 (PMA P230009) for colorectal cancer screening in adults 45 and older at average risk, with the instruction that "patients with a positive result should be followed by colonoscopy" and that it is "not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals." Approval rested on the ECLIPSE study, published in the New England Journal of Medicine in March 2024, which compared Shield with colonoscopy in 7,861 evaluable adults eligible for screening. In July 2026 the FDA approved a change to how Shield classifies results (supplement S010, a methylation-only model). We found no published performance figures for the changed test; the figures below are from the original ECLIPSE study, which Guardant still cites.
| Measure | Result |
|---|---|
| Colorectal cancers detected (sensitivity) | 83.1% (95% CI 72.2 to 90.3) |
| Stage I to III cancers detected | 87.5% |
| Advanced precancerous lesions detected | 13.2% (95% CI 11.3 to 15.3) |
| People without advanced neoplasia who tested negative (specificity) | 89.6% |
| Positive results per 1,000 people without advanced neoplasia | About 104 |
Two things follow. First, Shield is a cancer-finding test more than a prevention test. Colonoscopy, and to a lesser degree stool tests, can find precancerous growths so they are removed before they turn into cancer; Shield missed about 87 of every 100 such growths in the study, and Guardant's own materials say it has limited detection (55% to 65%) of stage I cancer. Second, roughly one in ten people without advanced growths gets a positive result and a colonoscopy that finds nothing serious. On Medicare that colonoscopy costs nothing unless a polyp is removed, but it is still a procedure, with bowel preparation, sedation and a small risk of complications.
What the guideline bodies say
The American Cancer Society's guideline page, last revised May 27, 2026, lists blood-based tests under "other test options": "Blood-based screening tests are not preferred screening options at this time," and "You should only use a blood-based test if you're not willing to get a stool-based test or visual exam." It gives no interval for them. The USPSTF's 2021 recommendation, the one federal coverage rules follow for private plans, "does not include serum tests, urine tests, or capsule endoscopy for colorectal cancer screening" because of limited evidence. Guardant says the NCCN guideline includes Shield; we could not read NCCN's text, which requires a login.
What three years of screening costs Medicare, by test
| Test | How often (Medicare) | Medicare pays the lab per test | Over 3 years |
|---|---|---|---|
| Fecal immunochemical test (FIT) | Every year | $18.05 (code G0328) | $54.15 |
| Multi-target stool DNA, original Cologuard | Every 3 years | $508.87 (code 81528) | $508.87 |
| Multi-target stool DNA, next-generation markers | Every 3 years | $591.92 (code 0464U) | $591.92 |
| Shield blood test | Every 3 years | $1,495.00 (code 0537U) | $1,495.00 |
On Original Medicare all four cost you nothing, so this table is about value, not your bill: the blood test costs the program about 28 times as much as three years of FIT, and the ACS lists FIT and the stool DNA test among its main options while calling the blood test not preferred. For a reader paying cash or facing a deductible, the gap is the reason to ask about a stool test first. Our guide to Cologuard versus colonoscopy compares those two in detail.
Who Shield is for, and who should skip it
A reasonable fit: someone at average risk who has put off screening because they will not do a colonoscopy or a stool test, and would do a blood draw. That is the group the ACS guideline names.
- Not for you if you have symptoms such as blood in the stool, a change in bowel habits or unexplained weight loss. That calls for a diagnostic evaluation, usually a colonoscopy, not a screening test, and Medicare's rule excludes people with symptoms.
- Not for higher-risk people: a personal history of colorectal cancer or adenomas, inflammatory bowel disease, or a family history of colorectal cancer or an inherited syndrome. Guardant's own limitations say the same.
- Not within six months of a positive result on another colorectal screening test, per Guardant's limitations. A positive stool test needs a colonoscopy, not a second opinion from a blood test.
- Over 85: Medicare's coverage ends at 85; our guide on when to stop colonoscopies covers the decision after 75.
Questions to ask before you order it
- Would I do a stool test or a colonoscopy instead? If yes, those are the preferred options.
- If the result is positive, where would I have the colonoscopy, and is it covered as screening on my plan?
- On Medicare Advantage or private insurance: will you confirm in writing what I will owe for Shield and for a follow-up colonoscopy?
- When would I repeat it? Medicare covers it every 3 years; results take about two weeks, per Guardant.
What we checked and what we did not
We read the FDA approval record, the ECLIPSE abstract on PubMed (title checked), Medicare's coverage determination NCD 210.3, 42 CFR 410.37, Medicare.gov's blood-based test and colonoscopy pages, CMS's 2026 fee schedule and its list of advanced diagnostic laboratory tests (which ties code 0537U to Shield at $1,495), Guardant's coverage and FAQ pages, the ACS guideline page and the USPSTF recommendation, all on November 16, 2026. We did not read NCCN's guideline, UnitedHealthcare's coverage policy, or the FDA's updated labeling.
Every figure, price and coverage rule on this page was checked against the pages listed under Sources on November 16, 2026. We did not take the test.
Frequently asked questions
How much does the Shield blood test cost?
On Original Medicare, $0 once every 3 years if you are 45 to 85, at average risk, without symptoms, and the provider accepts assignment. Without coverage, Guardant lists a cash price of $1,495, which is also what Medicare pays per test.
Does Medicare cover the Shield blood test?
Yes, under NCD 210.3, once every 3 years for people 45 to 85 at average risk with no symptoms. A colonoscopy after a positive result is covered as part of the screening.
Is Shield as good as a colonoscopy?
No. In its approval study it detected 83.1% of colorectal cancers and 13.2% of advanced precancerous lesions, while a colonoscopy can find and remove precancerous growths. The ACS calls blood tests not preferred and reserves them for people who will not do a stool test or a visual exam.
What happens if my Shield test is positive?
You need a colonoscopy. On Original Medicare it is covered as a screening test, so you pay nothing unless a polyp is removed, when 15% coinsurance applies. In the study, about 104 of every 1,000 people without advanced growths tested positive.
Does private insurance cover Shield?
It is not required to at no cost, because the USPSTF recommendation that private-plan preventive coverage follows does not include blood tests. Guardant says UnitedHealthcare covers it; ask your plan.